* female participants must not be pregnant and/or lactating * have acute respiratory distress syndrome (ards) or will require immediate intermittent mandatory ventilation (imv), or are ineligible for imv * have any concurrent serious medical condition (for example dialysis) or concomitant medication that would preclude participation in the study * are moribund irrespective of the provision of treatments * have a known history or show evidence of human immunodeficiency virus (hiv) and/or hepatitis * have recently undergone major surgery or central venous access device placement * have a significant bleeding disorder or active vasculitis * have experienced a thromboembolic event * have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia * have a serious, nonhealing wound, peptic ulcer, or bone fracture * have liver cirrhosis * have a known sensitivity to monoclonal antibodies (mabs) or other therapeutic proteins * have a history of hypertensive crisis or hypertensive encephalopathy or current, poorly controlled hypertension

* female participants must not be pregnant and/or lactating * have acute respiratory distress syndrome (ards) or will require immediate intermittent mandatory ventilation (imv), or are ineligible for imv * have any concurrent serious medical condition (for example dialysis) or concomitant medication that would preclude participation in the study * are moribund irrespective of the provision of treatments * have a known history or show evidence of human immunodeficiency virus (hiv) and/or hepatitis * have recently undergone major surgery or central venous access device placement * have a significant bleeding disorder or active vasculitis * have experienced a thromboembolic event * have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia * have a serious, nonhealing wound, peptic ulcer, or bone fracture * have liver cirrhosis * have a known sensitivity to monoclonal antibodies (mabs) or other therapeutic proteins * have a history of hypertensive crisis or hypertensive encephalopathy or current, poorly controlled hypertension

- female participants must not be pregnant and/or lactating - have acute respiratory distress syndrome (ards) or will require immediate intermittent mandatory ventilation (imv), or are ineligible for imv - have any concurrent serious medical condition (for example dialysis) or concomitant medication that would preclude participation in the study - are moribund irrespective of the provision of treatments - have a known history or show evidence of human immunodeficiency virus (hiv) and/or hepatitis - have recently undergone major surgery or central venous access device placement - have a significant bleeding disorder or active vasculitis - have experienced a thromboembolic event - have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia - have a serious, nonhealing wound, peptic ulcer, or bone fracture - have liver cirrhosis - have a known sensitivity to monoclonal antibodies (mabs) or other therapeutic proteins - have a history of hypertensive crisis or hypertensive encephalopathy or current, poorly controlled hypertension

- female participants must not be pregnant and/or lactating - have acute respiratory distress syndrome (ards) or will require immediate intermittent mandatory ventilation (imv), or are ineligible for imv - have any concurrent serious medical condition (for example dialysis) or concomitant medication that would preclude participation in the study - are moribund irrespective of the provision of treatments - have a known history or show evidence of human immunodeficiency virus (hiv) and/or hepatitis - have recently undergone major surgery or central venous access device placement - have a significant bleeding disorder or active vasculitis - have experienced a thromboembolic event - have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia - have a serious, nonhealing wound, peptic ulcer, or bone fracture - have liver cirrhosis - have a known sensitivity to monoclonal antibodies (mabs) or other therapeutic proteins - have a history of hypertensive crisis or hypertensive encephalopathy or current, poorly controlled hypertension